Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Palbinone is a terpenoid small molecule isolated from the roots of *Paeonia albiflora* Pallas. It is recognized for its potent *anti-inflammatory* activity and strong inhibitory effects on specific metabolic enzymes. Mechanistically, palbinone inhibits *aldose reductase (AKR1B1)* and *NADPH-linked 3 alpha-hydroxysteroid dehydrogenase*, enzymes that play important roles in carbohydrate metabolism and steroid hormone metabolism[1][3][5][6]. Preclinical studies have shown palbinone reduces retinal inflammation and oxidative stress, activates the Nrf2 antioxidant pathway, and inhibits NLRP3 inflammasome formation in diabetic retinopathy models[2]. Primary research suggests palbinone may improve antioxidant enzyme levels and modulate key inflammatory signaling pathways (such as NLRP3, IL-1β, and IL-18). Palbinone is currently used primarily as an investigative agent in biochemical and pharmacological research[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on palbinone.